Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B.

Abstract

BACKGROUND AND AIMS:

Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment naïve chronic hepatitis B (CHB) patients. However, little is known about the treatment modification and adherence on such patients with prolonged NA treatment.

METHODS:

In this multicenter observational study, a total of 600 NA-naïve Taiwanese CHB patients aged 16 years and older were enrolled. The 600 patients were retrospectively identified by their NA treatment history from August 2008 to July 2009; this cohort was prospectively followed up over 3 years. During the 3-year period, incidence of treatment modifications, reasons for modification, and rate of adherence were evaluated.

RESULTS:

Among the 583 evaluable patients, the initial NA treatment included entecavir (ETV) in 468 patients, telbivudine (LdT) in 67, and lamivudine (LVD) in 48. During the 3-year treatment, 9.0% of ETV-treated patients, 38.8% of LdT-treated patients, and 54.2% of LVD-treated patients had treatment modification. The main reasons for treatment modification were fulfilling stopping criteria in the ETV group (40.5%) and virological breakthrough in both the LdT (61.5%) and LVD (46.2%) groups. The proportion of patients with adherence rate (> 90%) at year 3 was 90.8% in the ETV group, 83.9% in the LdT group, and 83.9% in the LVD group.

CONCLUSIONS:

Treatment-naïve CHB patients with a 3-year ETV treatment in Taiwan have the lower likelihood of treatment modification and better rate of adherence compared with those with LdT or LVD treatment.

• Authors: Rong-Nan Chien, Cheng-Yuan Peng, Jia-Horng Kao, Tsung-Hui Hu, Chun-Che Lin, Chi-Tan Hu, Chi-Yi Chen, Tsai-Yuan Hsieh, Han-Chieh Lin, Wan-Long Chuang, Taiwan NA-Registry Group
• Journal: Journal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 29 Issue 1 Pg. 185-92 (Jan 2014) ISSN: 1440-1746 [Electronic] Australia
• PMID: 24354995 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Chemical References

• Antiviral Agents
• Dihydropyridines
• Lamivudine
• entecavir
• Guanine
• teludipine

Topics

• Administration, Oral
• Adolescent
• Adult
• Antiviral Agents (administration & dosage)
• Cohort Studies
• Dihydropyridines
• Female
• Follow-Up Studies
• Guanine (administration & dosage, analogs & derivatives)
• Hepatitis B (drug therapy, psychology)
• Humans
• Lamivudine
• Male
• Middle Aged
• Patient Compliance (statistics & numerical data)
• Prospective Studies
• Taiwan (epidemiology)
• Time Factors
• Young Adult